Abstract: A prokaryotic expression system or a recombinant adenovirus system is used to highly efficiently express VZV envelope gE glycoprotein and the flagellin fusion protein thereof. The produced recombinant gE protein, gE flagellin fusion protein and recombinant adenovirus vector, or composition thereof is used to immunize a mouse so as to promote the body to generate gE and VZV-specific antibody titer, as well as gE-specific and VZV-specific cell immunity.

Abstract: The present invention relates in general to the field of immunization, and particularly, an immunogenic preparation against Clostridium difficile infection (CDI), and a method for generating immunity against CDI by administering the immunogenic preparation to a subject in need. The present invention is useful for prevention and treatment of CDI and associated disease or disorder.

Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.

Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.

Abstract: A composition in a water-in-oil-in-water (W/O/W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising H2O; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W/O/W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W/O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-?-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Abstract: A composition in a water-in-oil-in-water (W/O/W) emulsion is disclosed. The composition comprises: (a) a continuous aqueous phase, comprising H2O; (b) an oil phase or an oil shell, dispersed in the continuous aqueous phase; and (c) a hydrophilic polymer, stabilizing an interface between the continuous aqueous phase and the oil phase or the oil shell to form the water-in-oil-in-water (W/O/W) emulsion. The oil phase or the oil shell comprises: (i) oil; (ii) an internal aqueous phase, dispersed within the oil or the oil shell; and (iii) a lipophilic sorbitan-polyester conjugate, stabilizing an interface between the oil and the inner aqueous phase to form a water-in-oil (W/O) emulsion. The lipophilic sorbitan-polyester conjugate comprises: (1) sorbitan; and (2) poly(lactide-co-?-caprolactone) or polylactic acid (polylactide), conjugated to the sorbitan.

Abstract: The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist.

Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.

Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.

Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

Abstract: Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.

Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.

Abstract: A method of producing a recombinant lipidated polypeptide in E. coli. The method includes providing an E. coli host cell adapted to express a recombinant lipidated polypeptide; and culturing the E. coli host cell in a minimal medium under conditions that allow expression of the polypeptide in lipidated form.

Abstract: A method for preparing and purifying recombinant lipoprotein Ag473 of Neisseria meningitidis (NM) group B isolates. The method can be used in large-scale production of vaccines for Neisseria meningitidis (NM) group B.

Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

Abstract: This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide.

Abstract: Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods.

Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.

Abstract: Disclosed are lipopeptides or lipoproteins, related compositions, and related methods.